|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.004 AUD | 0.00% |
|
0.00% | +14.29% |
| Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
| Mar. 14 | Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug | MT |
Avecho Biotechnology Limited reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was AUD 1.13 million compared to AUD 0.7936 million a year ago. Net loss was AUD 2.34 million compared to AUD 3.42 million a year ago.
Basic loss per share from continuing operations was AUD 0.0013 compared to AUD 0.0019 a year ago. Diluted loss per share from continuing operations was AUD 0.0013 compared to AUD 0.0019 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 8.27M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
AVECHO BIOTECHNOLOGY LIMITED 
